Review
Aug 2026
Evaluating the cost-effectiveness of respiratory syncytial virus vaccination among risk-stratified older adults.
RSV vaccination averts more quality-adjusted life-years (QALYs) from RSV than vaccine-associated GBS, and if RSV disease had higher incidence, costs, or mortality, vaccination would be more cost-effective.
D. W. Hutton, L. A. Prosser, I. Ortega-Sanchez et al.
· Vaccine · 0 citations